İyileşme & Onarım

Abaloparatide is an FDA-approved anabolic bone-building agent and synthetic analog of parathyroid hormone-related protein (PTHrP). It selectively activates the PTH1 receptor to stimulate new bone formation while minimizing bone resorption. In the phase III ACTIVE trial, abaloparatide showed superior BMD increases at the hip compared to teriparatide, with substantial fracture risk reduction. It was approved in the US in 2017 and EU in 2022 for postmenopausal women and men with osteoporosis at high fracture risk.

Synthetic copper-binding tripeptide targeting dermal papilla cells and hair follicles. Stimulates hair follicle elongation, promotes cell proliferation, increases VEGF production, and inhibits TGF-β1. Supports skin regeneration through fibroblast activation and collagen synthesis.

Ara 290 is an engineered 11-amino acid peptide activating the Innate Repair Receptor (IRR) to provide tissue-protective effects without red blood cell stimulation. Has FDA Orphan Drug status.

B7-33 is a single-chain peptide analog of human relaxin-2 that selectively activates the relaxin family peptide receptor 1 (RXFP1). Unlike native relaxin-2, which requires a complex two-chain A/B structure connected by disulfide bonds, B7-33 achieves RXFP1 activation with a much simpler single-chain design. This makes it significantly easier and more cost-effective to synthesize. Preclinical research demonstrates potent anti-fibrotic, vasodilatory, and cardioprotective properties, positioning B7-33 as a promising therapeutic candidate for fibrotic diseases, heart failure, and vascular dysfunction.

Synthetic peptide derived from gastric juice protein, renowned for tissue repair, inflammation reduction, and GI protection capabilities. BPC-157 promotes blood vessel formation, enhances collagen synthesis, modulates growth factor expression, and protects against tissue damage through localized or systemic delivery.

Cardiogen is a Khavinson bioregulator peptide consisting of four amino acids, derived from heart tissue research. Unlike larger peptides that work on cell surfaces, Cardiogen penetrates directly to the cell nucleus where it binds to specific DNA regions to regulate gene expression. This epigenetic mechanism supports tissue repair and improves cardiovascular function, particularly benefiting the heart and blood vessels.

Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation.

Naturally occurring copper tripeptide found in human plasma, saliva, and urine. GHK-Cu affects 31.2% of human genes and declines significantly with age—from ~200 ng/ml at age 20 to ~80 ng/ml at age 60. Known for exceptional skin regeneration, wound healing, and anti-aging properties.

Combination featuring BPC-157, TB-500, and GHK-Cu marketed for skin rejuvenation and anti-aging. Individual components have research support, but combination protocols require careful dosing to avoid exceeding therapeutic ranges.

Human Growth Hormone (HGH/Somatropin) is a 191-amino acid polypeptide hormone FDA-approved for pediatric and adult growth hormone deficiency, HIV-associated wasting, and other conditions. It provides both direct and indirect (IGF-1 mediated) anabolic effects.

IGF-1 LR3 is a synthetic 83-amino acid analog of insulin-like growth factor-1 that has never been approved for human use. The N-terminal extension and R3 substitution reduce binding protein interaction, maintaining elevated free circulating levels with ~3x greater potency than native IGF-1.

KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH, making it ideal for inflammation management.

LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide derived from hCAP18 that exhibits broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while modulating immune responses.

Non-pegylated IGF-1 splice variant produced locally in muscle tissue following mechanical stress. Has a very short half-life compared to PEG-MGF, requiring more frequent administration or localized injection.

Nandrolone is a synthetic 19-nortestosterone anabolic-androgenic steroid that has been in clinical use since the 1960s. Structurally, it differs from testosterone by the absence of a methyl group at the C19 position, which significantly reduces its androgenic activity relative to its anabolic potency. Nandrolone decanoate (Deca-Durabolin) was FDA-approved for the treatment of anemia associated with chronic renal failure and has also been used clinically for osteoporosis, wasting diseases, and severe burn recovery. Among anabolic steroids, nandrolone is particularly valued for its positive effects on collagen synthesis, joint health, and bone mineral density. It has one of the most favorable anabolic-to-androgenic ratios of any synthetic steroid (approximately 125:37 compared to testosterone at 100:100), making it a frequent choice for individuals seeking muscle growth with reduced androgenic side effects. Nandrolone is available in two primary ester formulations: the long-acting decanoate ester and the shorter-acting phenylpropionate ester (NPP).

Oxandrolone is a synthetic oral anabolic-androgenic steroid derived from dihydrotestosterone (DHT), first synthesized in 1962 by Raphael Pappo at Searle Laboratories and introduced to the market in 1964 under the brand name Anavar. It was designed to be a mild anabolic agent with minimal androgenic activity, achieved through a structural modification where an oxygen atom replaces the carbon-2 atom in the A-ring of the DHT backbone. This modification significantly reduces androgenic potency while preserving anabolic effects on skeletal muscle. Oxandrolone is FDA-approved for the promotion of weight regain following involuntary weight loss due to surgery, chronic infection, severe trauma, and prolonged corticosteroid use, and for the relief of bone pain associated with osteoporosis. It has been extensively studied in burn recovery, HIV/AIDS-related wasting, and pediatric growth disorders. Among oral anabolic steroids, oxandrolone is considered one of the mildest with respect to hepatotoxicity and virilizing side effects, which has made it one of the few anabolic steroids used in women and children in clinical settings.

Modified IGF-1 variant with PEG attachment extending half-life from minutes to hours. Activates muscle satellite cells following mechanical stress or injury.

A synthetic 7-amino acid fragment corresponding to the actin-binding region of thymosin beta-4, originally developed for equine use with retained tissue repair properties. TB-500 acts as principal actin-sequestering protein, regulating cell migration, promoting angiogenesis, reducing inflammation, and activating stem cell differentiation.

TB-500 (Ac-LKKTETQ) is a synthetic derivative of thymosin beta-4 consisting of the N-terminal acetylated 17-23 amino acid fragment. This sequence represents the active site within thymosin beta-4 responsible for actin binding, cell migration, and wound healing. Research shows it promotes endothelial cell differentiation, angiogenesis, keratinocyte migration, collagen deposition, and decreases inflammation. The acetylation protects against N-terminal degradation while maintaining biological activity.

Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation. The key to its mechanism is intermittent exposure: while continuous PTH causes bone resorption, daily injections stimulate osteoblasts more than osteoclasts, resulting in net bone formation. Clinical trials show 8% spine bone density increases and 65% reduction in vertebral fractures.

Naturally occurring 43-amino acid peptide crucial for tissue repair, wound healing, and cellular regeneration. Promotes angiogenesis, reduces inflammation, and supports cell migration and differentiation.

Tri-Heal Max is an enhanced healing peptide blend featuring a higher dose of TB-500 (25mg) combined with BPC-157 (10mg) and KPV (10mg) for a total of 45mg per vial. This formulation emphasizes TB-500's tissue repair and cellular migration properties, complemented by BPC-157's growth factor upregulation and KPV's anti-inflammatory effects. The higher TB-500 ratio (2.5:1:1) compared to standard healing stacks targets more significant tissue damage or accelerated recovery needs.

Vesugen is a Khavinson bioregulator tripeptide developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology. Composed of three amino acids (lysine, glutamic acid, aspartic acid), it targets the vascular system and protects blood vessels from age-related decline. Research shows it limits atherosclerosis development, decreases endothelial dysfunction, and activates stem cells. Like other short Khavinson peptides, Vesugen penetrates to the nucleus where it influences gene expression.

Combines BPC-157 and TB-500 for synergistic tissue repair and recovery. 87.5% improvement in knee pain patients per Lee & Padgett 2021 study.